The Indian diabetes diagnosis and therapeutics market is anticipated to grow at a CAGR of 7% during the forecast period. Rising in the diabetic population is creating demand for diagnosis is driving the demand for Indian diabetes diagnosis and treatment market. According to the International Disease Foundation, around 73 million people in India are suffering from diabetes. According to the WHO, it is expected that India will go pass China by 2030 both in terms of population and diabetic population. Furthermore, the market for drugs and diagnosis is boosting the country that is providing a lucrative opportunity for healthcare companies. Additionally, increasing obesity level, rising trend of wearable devices and the development of new products for the treatment and diagnosis of diabetes are the other factors that are supporting the growth of the market.
Browse the full report description of "Indian Diabetes Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational), by Drug Type (Oral anti-diabetic Drugs, Non-Insulin Injectable drugs, and Combination Drugs), and by Device Type (Blood Glucose Monitoring Devices, Blood Glucose Strips, Insulin devices, and Others) Forecast Period (2022-2028)" at https://www.omrglobal.com/industry-reports/indian-diabetes-diagnosis-and-treatment-market
New product launches in the market
The companies are launching new products and solution in the market for obtaining a sustainable position in the Indian diabetes market. For instance, in April 2019, Glenmark launches an anti-diabetes drug Remogliflozin in India and it is the first company globally to launch Remogliflozin and India is the first country to get access for this drug. It is innovative and patent-protected sodium glucoseco-transporter-2 (SGLT2) inhibitors that indicate in adults in the treatment of type-2 diabetes mellitus. SGLT2 inhibitors are classes of oral anti-diabetes drugs that administer induce weight, reduce cardiovascular risks and glycemic control. These types of product launch offer sustainable growth in the market.
Trends in Indian diabetes diagnosis and therapeutics market
With the increase in Indian diabetic population, government institutions and pharmaceutical companies concentrating majorly on developing innovative products that propels the Indian diabetes market. Integration of the healthcare sector and information technology has led to the development of innovative products. Major market players such as Merck and Sanofi are at the forefront of innovations. Numerous research programs are being conducted across the globe with the aim to provide accurate as well as technologically advanced solution, for the monitoring & management of diabetes. Moreover, innovative products such as smart insulin have gained major attraction in the Indian market.
Development of Artificial Pancreas
Artificial pancreas technology is the next step in integrating insulin delivery systems and glucose monitors. US FDA and Juvenile Diabetes Research Foundation are working with continuous glucose monitors (CGMS) manufacturers to develop APD (Artificial Pancreas Devices). The FDA has laid down the guidelines for the design, use, safety, and shelf life of APD. The guidelines are aimed at increasing the pace of APD development to initiate the pre-market approval process. In March 2017, a new project on the development of artificial pancreas for closed loop blood glucose control of type-1 diabetic patients are initiated with the support of the Indian Council of Medical Research. The main aim of this project is to develop an effective artificial pancreas prototype for Type-1 diabetic patients.
Indian Diabetes Diagnosis and Treatment Market – Segmentation
By Disease Type
By Drug Type
By Device Type
Indian Diabetes Diagnosis and Treatment Market – Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/indian-diabetes-diagnosis-and-treatment-market